VivoSeq
Other

Non-Small-Cell Lung

5

Pipeline Programs↗

1

Active Trials↗

5

Companies Involved↗

Non-Small-Cell Lung is an early-stage landscape with 5 programs across 5 companies. The most active players are Merck & Co., AstraZeneca, Gynecologic Oncology Group. 5 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 3AstraZeneca logo

AstraZeneca

1 program

Phase 3G

Gynecologic Oncology Group

1 program

Phase 3A

Avyxa

1 program

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

4 of 5 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody120%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 100% of 5 pipeline programs.

Analysis

Trial Status

3

clinical trials

Unknown status1 · 33%
Recruiting1 · 33%
Completed1 · 33%

Clinical Trials

Trial Activity

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI
Unknown status·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT03924050·440 enrolled
A Multi-centre Chart Review Study on the Treatment Patterns and Outcomes of Stage I-III Non-Small Cell Lung Cancer in China
Recruiting·AstraZeneca logoAstraZeneca·N/A·NCT07316062·3,000 enrolled
A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT03976323·1,003 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)